GLP-3 R (retatrutide) is a novel multi-receptor agonist targeting GLP-1 and GIP studied for the treatment of obesity and metabolic disorders. It promotes weight loss by enhancing energy expenditure, reducing appetite, and improving insulin sensitivity. Early clinical trials have shown promising results, with significant reductions in mass and improvements in glycemic control, positioning Retatrutide as a potential breakthrough studied peptide.
Join our community
Subscribe for insights and exclusive updates.